NKG2D Ligands–Critical Targets for Cancer Immune Escape and Therapy

Frontiers in Immunology - Switzerland
doi 10.3389/fimmu.2018.02040
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Frontiers Media SA

Related search

HCC-Derived Exosomes: Critical Player and Target for Cancer Immune Escape

Cells
2019English

Immune Cells as Targets and Tools for Cancer Therapy

Immunotherapy: Open Access
2017English

Cancer Gene Therapy via NKG2D and FAS Pathways

2011English

Metabolic Targets for Cancer Therapy

Nature Reviews Drug Discovery
MedicineDrug DiscoveryPharmacology
2013English

Regulation of Ligands for the NKG2D Activating Receptor

Annual Review of Immunology
AllergyImmunology
2013English

Lynch Syndrome - Cancer Pathways, Heterogeneity and Immune Escape

Journal of Pathology
Forensic MedicinePathology
2018English

Murine Cytomegalovirus Regulation of NKG2D Ligands

Medical Microbiology and Immunology
MedicineAllergyImmunologyMicrobiology
2008English

Murine NKG2D Ligands: “Double, Double Toil and Trouble”

Molecular Immunology
ImmunologyMolecular Biology
2009English

Antibody-Nkg2d Ligand (Rae-1Beta) Fusion Protein for Breast Cancer Therapy

2005English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy